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• Fetal hydrops is the abnormal accumulation of fluid in two or more 
extravascular fetal compartments. 
• Fetal hydrops confers a high risk of morbidity and mortality. 
• Fetal hydrops can be divided into immune (largely materno-fetal 
alloimmunisation) and non-immune. 
• Non-immune fetal hydrops can be caused by a multitude of different causes 
including infection, congenital malformation, chromosome abnormalities and 
single-gene disorders. 
• The identification of fetal anaemia from the second trimester is crucial to 
guiding further investigations. 
• Many cases of fetal hydrops remain undiagnosed and we believe a significant 
proportion of these have underlying genetic lymphatic dysplasias. 
• As exome or whole genome sequencing becomes increasingly available, 










Introduction: Fetal hydrops describes abnormal fluid accumulation in two or more 
extravascular fetal compartments. It is a poor prognostic sign in a fetus, and many 
will not survive to term. Fetal hydrops is a clinical sign rather than a diagnosis and 
has a multitude of different causes. 
Areas covered: This review focusses on non-immune fetal hydrops. We discuss in 
detail the most common aetiologies such as infection and chromosomal 
abnormalities and cover rarer presentations of congenital malformation and single-
gene disorders. We present a decision tree for the investigation of affected 
pregnancies. 
Expert Opinion: The current approach to the investigation of fetal hydrops largely 
revolves around identifying the abnormal pathophysiology via ultrasound imaging. 
We believe that as genomic testing of a pregnancy can be undertaken with 
increasing accuracy, speed, accessibility and at reduced cost, genetic testing will 






Fetal hydrops, the abnormal accumulation of fluid in two or more fetal compartments, 
affects approximately 1 in 1,700 pregnancies [1]. Fetal hydrops can occur at any point in a 
pregnancy. In the first trimester the first sign is typically a raised nuchal translucency on 
fetal ultrasound. The nuchal translucency is the region of the back of the fetal neck which 
increases in size when there is subcutaneous oedema or enlarged jugular lymphatic sacs 
(Figure 1). When there are two or more of: pericardial effusion, pleural effusion, ascites or 
generalised skin oedema, fetal hydrops can be diagnosed. (Figure 2). Placental 
thickening/oedema and polyhydramnios (increased amniotic fluid levels) can be seen in 
cases of fetal hydrops, but are not critical features for the diagnosis. The identification of 
fetal hydrops should prompt urgent referral to a centre with maternal-fetal medicine 
expertise. Ultrasound imaging (including Doppler studies), as well as a thorough maternal 
obstetric and family history, can help to make a diagnosis, guide treatment and estimate 
prognosis. 
In a study of 167 hydropic fetuses (all causes), 66% died before or shortly after birth [2]. In a 
Japanese study of 214 cases of ‘non-immune fetal hydrops’ (discussed below), 91 (43%) 
survived the perinatal period, 79 (37%) were alive at one year of age and only 30 of the 58 
(52%) followed for more than one year had age-appropriate neuro development [3]. Thus, 
fetal hydrops is an important indicator of mortality and morbidity. 
Fetal hydrops is a sign, rather than a diagnosis in its own right. As such it is essential to 
attempt to identify the underlying cause of the hydrops. In some cases, knowledge of the 
underlying cause will allow for the prompt instigation of treatment, which will have a 
positive impact on fetal survival or inform neonatal care. In other cases, knowledge of an 
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underlying genetic abnormality will provide useful information to the parents about the 
prognosis for the pregnancy/child and the recurrence risk for future pregnancies. 
Many excellent papers discuss the varied aetiologies of fetal hydrops. Most attempt to 
classify the underlying diagnosis into broad system-specific categories. This is fraught with 
difficulty as many conditions overlap and could be justifiably placed in a number of different 
categories. For example, fetuses with monosomy X (Turner Syndrome) could be described 
as chromosomal, lymphatic, cardiac and syndromic. This paper approaches the aetiology 
from a clinical perspective. 
2. Pathophysiology of fetal hydrops 
Fetal hydrops follows the same physiological rules as any other oedema. Oedema is an 
excess of interstitial fluid and can develop in the subcutis, lungs (pulmonary oedema), 
abdominal cavity (ascites), or other body cavities (pleural or pericardial effusions) [4]. 
Oedema occurs when capillary filtration rate exceeds lymph drainage rate for a period of 
time. Oedema can therefore occur from a raised capillary filtration rate, or reduced lymph 
drainage rate, or a combination of the two. Circumstances in which these scenarios occur 
are as follows [5]: 
2.1 ‘Impairment of lymphatic drainage’ 
Lymphatic drainage is the rate limiting step for all oedema [6]. Lymph fluid re-joins the 
venous circulation at the junction of the subclavian and internal jugular veins. Impairment of 
lymphatic flow can result from malformation of the lymphatic system, compression of 
lymph vessels from an external mass or reduced flow due to reduced fetal movements and 
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so lead to fetal oedema. In a report of 79 fetuses affected by fetal akinesia sequence 31.3 % 
developed hydrops [7]. 
2.2 ‘Increase in hydrostatic capillary pressure’ 
An increase in hydrostatic capillary pressure changes the Starling forces in favour of 
increased microvascular filtration and therefore increased lymph production. An increase in 
hydrostatic capillary pressure results from an increase in venous pressure owing to 
obstruction of venous drainage or increase in central venous pressure. This leads to greater 
amounts of fluid filtering from the blood circulation into the interstitium. Conditions leading 
to increased capillary hydrostatic pressure include some congenital heart disease 
(arrhythmias and cardiomyopathy), vascular malformations and anaemia (causing high 
output heart failure) [5]. 
2.3 ‘Reduction in intravascular osmotic pressure’ 
Intravascular proteins exert an osmotic pressure, which control how much fluid leaves the 
circulation. In states of hypoproteinaemia, the colloid osmotic pressure of the blood is 
decreased, and less fluid is retained within the circulation but released into the interstitium 
leading to oedema. Inborn errors of metabolism and nephrotic syndrome are the most likely 
potential causes of hypoproteinaemia in the fetus [8]. 
2.4 ‘Damage to peripheral capillary integrity’ 
The blood capillary wall has a basic level of leakiness (permeability) to fluids and small 
solutes, which increases in inflammatory states. Fetal anaemia (in addition to uteroplacental 
insufficiency) leads to anoxic damage to cells and decreased capillary wall integrity [9]. With 
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increased capillary permeability, proteins leak into the interstitium causing an increase of 
the interstitial colloid osmotic pressure, which in turn leads to increased fluid loss from the 
blood capillaries into the interstitium and resultant oedema. 
3. Identification of the cause of hydrops 
We have presented the causes of fetal hydrops within a clinical decision framework. Figure 
3 describes the process by which a clinician will prioritise investigations in an attempt to 
identify the cause of hydrops when presented with an affected pregnancy.  In the first 
trimester fetal hydrops usually results from chromosome abnormalities and microarray 
CGH, via an invasive test of the pregnancy, is a first line investigation. From the second 
trimester the number of potential causes of fetal hydrops is great and investigation usually 
starts with the measurement of the middle cerebral artery to identify the peak systolic 
velocity (MCV-PSV). Where the MCV-PSV is high further investigations can be targeted 
toward the identification of the cause of fetal anaemia. Where the MCV-PSV is normal, and 
the fetus is not anaemic, ultrasound examination can be used to identify those fetuses with 
thoracic space occupying lesions and those with primary cardiac abnormalities.  Those 
fetuses without space occupying lesions or primary cardiac abnormalities can be 
investigated on the basis of the ultrasound phenotype and are the group most likely to 
benefit from genomic sequencing. See Figure 3 for a diagrammatic representation of this 
investigatory pathway. 
4. Evidence of Fetal Anaemia 
Evidence of fetal anaemia will lead to further investigations as outlined below. (Figure 3). 
4.1 Immune Fetal Hydrops 
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4.1.1 Rhesus alloimmunisation 
Rhesus alloimmunisation occurs when a rhesus negative mother has an immunological 
response to a paternally derived rhesus D antigen, in a rhesus positive baby. The mother 
produces anti-D antibodies, which cross the placenta and cause haemolysis of the fetal D-
antigen presenting erythrocytes leading to fetal anaemia (and subsequent fetal hydrops) 
[10,11]. The introduction of Rhesus D anti-sera in the 1970’s has almost eliminated this once 
common cause of immune fetal hydrops in the West, but it remains a common cause of 
fetal hydrops in developing countries. 
Alloimmunisation can occur to a number of other antigens on the surface of the fetal 
erythrocytes leading to hydrops or haemolytic disease of the newborn. The discussion of 
this is beyond the scope of this paper, but fully explained by Urbaniak and Griess (2000) 
[10]. 
4.1.2 Antiplatelet antibodies 
All human platelets exhibit proteins on their surface called human platelet antigens (HPAs), 
which are bi-parentally inherited. On rare occasions a pregnant mother can develop 
antibodies to the unrecognised paternally derived HPAs, which leads to fetal platelet 
destruction and thrombocytopaenia [12]. The commonest antibody is HPA-1A seen in the 
context of the maternal haplotype HLA DRB3*0101 [13,14]. Severe fetal thrombocytopaenia 
can cause fetal haemorrhage, typically intracerebral, in the third trimester. Fetal 
haemorrhage can cause fetal hydrops by way of fetal anaemia [12,15,16]. 
4.2 Non-immune causes of fetal anaemia 
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4.2.1 Fetal haemorrhage 
Fetal haemorrhage, whether internal (intracerebral or subdural) or feto-maternal, can lead 
to anaemia and therefore non-immune fetal hydrops [17]. Feto-maternal haemorrhage is 
the loss of fetal blood into the maternal circulation. Feto-maternal haemorrhages can occur 
in isolation or occur as chronic, slow bleeds. 
Often there are minimal symptoms of a fetal haemorrhage but reported reduction in fetal 
movements should raise suspicion. An assessment for fetal anaemia should then be 
promptly undertaken. The Kleihauer-Betke smear performed on a maternal blood sample 
will identify the presence of fetal erythrocytes in many (but not all) cases of fetal maternal 
haemorrhage [18]. Imaging, such as fetal ultrasound or MRI, can be used for the assessment 
of internal fetal haemorrhage (the majority of which will be intracerebral). Fetal blood 
transfusion can improve or reverse the fetal hydrops but there may be proceeding 
neurological injury [19]. 
4.2.2 Infection 
 Erythema infectiosum (also known as fifth disease) is a common disease of childhood and 
mainly causes a mild flu-like illness with or without pruritus and erythematous malar rash 
(‘slapped cheek’). The condition is most frequently caused by contact with respiratory 
droplets infected with Parvovirus B19 (PB19), a single-stranded DNA virus. By reproductive 
age just over half of women are immune to PB19 [20,21]. However, an additional 1.5% of 
pregnant women seroconvert each year during endemic periods [22]. 
In approximately one quarter of cases the infection is vertically transmitted (transplacental) 
to the fetus, yet only a minority of those fetuses, biochemically proven to be infected, will 
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have an adverse outcome as a result [23]. Parvovirus has an affinity for erythroid progenitor 
cells leading to their infection and apoptosis [24]. This can result in fetal anaemia as 
evidenced by increased middle cerebral artery peak systolic velocity (MCA PSV), high output 
cardiac failure and subsequent fetal hydrops. 
Parvovirus B19 infection accounts for approximately 4% of all cases of fetal hydrops (7.1% 
when the infection occurs between weeks 14 and 20 of pregnancy) [25]. Hydrops in these 
cases results from infection of erythroid progenitor cells, shortened erythroid cell life span 
and high output cardiac failure, aggravated by direct infection of cardiac myocytes leading 
to myocarditis [26]. In about one third of cases the fetal anaemia/fetal hydrops resolves 
spontaneously. Less frequently parvovirus B19 infection, particularly in the first half of a 
pregnancy, can lead to brain anomalies resulting in neurodevelopmental disorders [27]. The 
presence of fetal hydrops is the strongest predictor of fetal mortality in this group [28]. 
Other maternal infections that have been associated with fetal hydrops include 
Cytomegalovirus, Toxoplasma gondii, Treponema pallidum, herpes simplex virus (HSV) and 
Zika Virus [29–31]. The mechanism is thought to be anaemia, secondary to bone marrow 
infection, causing red cell aplasia, or direct effects of infection on cardiac myocytes leading 
to decreased cardiac efficiency [29]. Effects on bone marrow would be causative of hydrops 
in the third trimester when the fetal bone marrow becomes primarily responsible for red 
cell production. 
There is good evidence that intra-uterine fetal blood transfusions can reverse fetal anaemia 
and improve outcomes in these cases [32,33]. 
4.2.3 Twin-Twin Transfusion 
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Twin-twin transfusion syndrome (TTTS) is a serious complication of 10-15% of 
monochorionic multiple pregnancies and is the most significant cause of death in twin 
pregnancies [34]. The condition arises due to presence of vascular anastomoses between 
vessels belonging to each fetus within a shared placenta. The reason why not all 
monochorionic multiple pregnancies develop TTTS is not clear. 
The anastomoses can be arterial-arterial, vein-vein or arterial-venous and it is postulated 
that it is both the number and calibre of these anastomoses which determines severity. 
Where abnormal connections lead to unequal distribution of blood flow the ‘recipient’ twin 
can become polycythaemic, polyuric (leading to polyhydramnios) and hypertensive with 
fetal hydrops. The ‘donor’ twin is hypotensive, has poor growth and urine output with 
resulting oligohydramnios [35]. 
TTTS is staged using the Quintero system[36], which categorises cases by severity. Quintero 
stage one is the least severe with polyhydramnios only. In Stage two it is not possible to 
visualise the bladder of the donor fetus and is an indication for fetoscopic laser 
photocoagulation therapy. Quintero stage 3 describes flow abnormalities in the umbilical 
artery and vein on doppler ultrasound. Quintero stage four is defined by the presence of 
fetal hydrops [36]. Stage 5 indicates demise of one or more fetus. Laser photocoagulation 
therapy aims to divide the anastomoses and separate the fetal circulations. This significantly 
improves fetal survival, but approximately 10% of the surviving babies have adverse 




Alpha thalassemia is caused by mutations in the alpha-globin genes leading to a reduction or 
absence of their product: alpha-globin. The normal adult state is to have two alpha-globin 
genes tandemly encoded (in cis) on each of an individual’s two chromosome 16 (i.e. 4 alpha-
globin genes in total). During the embryonic stage the alpha-like globin, sigma-globin, forms 
a tetramer with two epsilon-globin chains. During the 6th week of gestation, erythropoiesis 
becomes a primary function of the fetal liver (rather than yolk sac) and fetal haemoglobin 
consisting of two alpha and two gamma-globulin chains are produced [38]. If a baby inherits 
a chromosome 16 with the alpha-globin genes deleted or has a pathogenic mutation in both 
alpha chains (--/--) from each parent, haemoglobin tetramers assembled will consist entirely 
of beta chains. This results in Hb-Barts (homozygous alpha-thalassaemia), which normally 
results in fetal loss (anaemia, hypoxia and non-immune fetal hydrops) in the third trimester 
[39]. Rarely, HbH disease (--/-a) has been identified as a cause of fetal hydrops [40]. 
Most alpha-thalassaemias are deletional in genetic aetiology [41]. However, the severity of 
those alpha-thalassaemias caused by mutations is dependent on the extent to which the 
mutation causes reduction in protein product. A specific deletional mutation found in 
Southeast Asia (--SEA) accounts for more than 90% of cases of non-immune fetal hydrops in 
this geographical region [42]. 
Beta-thalassaemia is caused by mutations in the HBB gene which encodes the haemoglobin 
B subunit that gradually replaces the gamma-globulin chains specific to fetal haemoglobin. 
As the shift to beta-globin subunits does not occur until post-natal life, HBB mutations are 
not a cause of fetal hydrops. 
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4.2.5 Congenital anaemias 
4.2.5.1 Diamond-Blackfan Syndrome 
Diamond-Blackfan Syndrome, first characterised in 1938, is a rare inherited bone marrow 
failure syndrome [43]. Mutations in 19 ribosome protein encoding genes have been 
implicated in this condition [44] as well as mutations in GATA1 [45] and TSR2 [46]. 
Complications include congenital structural abnormalities such as orofacial, hand, 
genitourinary and cardiac abnormalities (50% of cases), growth retardation (30% of cases) 
and predisposition to malignancy [47,48]. Skeletal manifestations are typically radial: 
triphalangeal, bifid or duplicated thumbs or radial hypoplasia [49]. Most cases present 
within the first year of life. Fetal hydrops is a poor prognostic indicator and results from 
severe intrauterine anaemia. It is a rare manifestation of Diamond-Blackfan, with fewer 
than 10 cases reported [50]. Specific truncating mutations in the ribosomal protein RPL15 
seem to confer the greatest risk of fetal hydrops [50]. First line treatment is with 
glucocorticoids with chronic blood transfusions and stem-cell transplants reserved for 
glucocorticosteroid non-responders. Cases presenting antenatally are treated with in-utero 
blood transfusions, first used in this condition in 1997 [49]. 
4.2.5.2 Congenital Dyserythropoietic Anaemia type 1 
Congenital dyserythropoietic anaemia type 1 (CDA I) is another rare bone marrow failure 
syndrome. Complications include macrocytic anaemia, bony abnormalities and secondary 
haemochromatosis. Most cases are caused by mutations in CDAN1 [51]. The product of 
CDAN1, codanin-1 is important for terminal erythrocyte differentiation, disruption of which 
leads to dyserythropoiesis [52]. So far fewer than ten cases of CDA I presenting as fetal 
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hydrops have been reported in the literature, only two of those had a molecular genetic 
diagnosis, both with mutations in CDAN1 [52,53]. Intrauterine blood transfusions have been 
used as a bridge to postnatal allogenic bone marrow transplant with varying degrees of 
success. Additional genes have been implicated in CDA (types 2 and 3 and rarer variants) 
although these have been less frequently associated with fetal hydrops, and tend to have a 
milder phenotype. 
4.2.5.3 Transient Abnormal Myelopoesis (TAM) in the context of Trisomy 21 
Individuals with trisomy 21 (Down syndrome) are at increased risk of myeloproliferative 
disorders throughout life [54] . A transient, abnormal myelopoesis (TAM) is recognised to 
affect approximately 10-15% of infants with trisomy 21 [55]. The trisomy 21 is responsible 
for an initial dysmegakaryopoesis and, with an acquired GATA1 truncating mutation, control 
of clonal proliferation of blasts cells is lost [56]. The result is a transient abnormal 
myelopoesis with up to 30% developing into myeloid leukaemia, by the age of 4 years, after 
acquisition of additional oncogenic driver mutations [57]. In a study by Tamblyn et al, of 31 
cases of prenatally diagnosed TAM, 79.5% had hepatosplenomegaly and 30.8% had fetal 
hydrops. In the 33% of cases with both fetal hydrops and hepatomegaly the fetal or early 
neonatal mortality was 92% (54% with fetal hydrops alone) [58]. Thus fetal hydrops is a poor 
prognostic sign as the survival rate for postnatally detected cases is in the region of 70% 
with most babies undergoing spontaneous resolution of the abnormal myelopoiesis [55,59]. 
A recent report shows promising results for in-utero treatment with exchange transfusions 
and low dose cytarabine [60]. 
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5 Non-anaemic with thoracic space occupying lesion on ultrasound 
Detailed fetal ultrasound may identify a space occupying lesion causing Impairment of 
lymphatic or venous drainage (Figure 3).  
5.1 Congenital Pulmonary Airway Malformation and Pulmonary Sequestrations 
A congenital pulmonary airway malformation (CPAM) of the lung is a developmental 
abnormality caused by the failure of maturation of the bronchiolar structures during lung 
development. This results in overgrowth of terminal bronchioles without alveoli [61]. These 
are usually identified at the 20-week anomaly scan. CPAMs can be microcystic, macrocystic 
or a mixed type. In up to 65% of cases, the CPAM will spontaneously regress, possibly due to 
outgrowing of its blood supply [62]. In a large retrospective study of CPAM affected 
pregnancies, those cases without fetal hydrops had a 95% chance of survival. Those cases 
which developed hydrops, and were managed expectantly, had a 95% risk of perinatal death 
[63]. 
Pulmonary sequestrations (PS) are collections of non-functional lung tissue, which may or 
may not be cystic in nature but can be differentiated on fetal ultrasound from CPAM by 
identifying a systemic (rather than pulmonary) arterial supply [64,65]. PS can lead to the 
development of pleural effusions, non-immune fetal hydrops and perinatal death. The 
treatment of the pleural effusions with thoracentesis, thoracoamniotic shunts, 
intraperitoneal injection of frusemide/digoxin and laser coagulation leads to survival in the 
majority (91/95 in the case review by Cavoretto et al) but many will go on to need repeat 
procedures such as postnatal sequestrectomy due to pleural effusion reaccumulation [63]. 
5.2 Cardiac tumours 
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The three most common types of cardiac tumour in fetuses, newborns and children are 
rhabdomyomas (60%), teratomas (25%) and fibromas (12%) [66]. On ultrasound, 
rhabdomyomas often present in multiple as homogenous, hyperechogenic masses of 
varying sizes [66]. They are considered to be hamartomas as they are overgrowths of tissue 
that is normally present rather than being neoplastic [67]. The masses are usually located in 
the ventricles and septal walls but are occasionally found in the atria and pericardium. In 
one metanalysis by Chao et al. (2008) of fetuses with cardiac rhabdomyomas, 63.9% 
(85/133) were identified as having tuberous sclerosis complex and more than 80% of those 
with multiple rhabdomyomas. The authors also found that larger tumours increased the risk 
of developing haemodynamic compromise and rhythm disturbance and in turn the 
development of non-immune fetal hydrops and a high risk of fetal demise [68]. Recently, 
mTOR inhibitors such as sirolimus have been used for intra-uterine treatment but this 
remains a matter of debate given the potential maternal side effects[182,183].  
Pericardial teratomas are germ-cell tumours found in the pericardium. They often cause 
significant pericardial effusions and mediastinal compression, which leads to reduced 
venous return and non-immune fetal hydrops. Whilst these tumours are rarely malignant 
and can be successfully treated postnatally, prognosis remains guarded. In fact, prognosis in 
this condition is more closely related to the development of the fetal hydrops than the 
malignant potential of the tumour [69]. Elective delivery, pericardiocentesis and 
thoracoamniotic shunting are the mainstays of in-utero teratoma therapy [70,71]. 
6 Non anaemic with cardiac abnormalities on ultrasound 
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Detailed fetal ultrasound may identify an abnormality of cardiac development as the 
primary cause (Figure 3). These include structural malformations, arrhythmias, 
cardiomyopathy or tumours.  
6.1 Structural cardiac malformations 
Abnormalities of cardiac development are a significant contributor to the total incidence of 
fetal hydrops. Some aetiological studies have determined that cardiac causes explain 
approximately 20% of all non-immune fetal hydrops [72]. Fetal cardiac echocardiography 
will identify many of these abnormalities and should be performed by a fetal cardiac 
specialist. Fetal echocardiography can be diagnostic from 13-14 weeks gestation. However, 
more subtle lesions may only become evident from 19-22 weeks gestation (e.g. ventricular 
septal defects). Screening of the fetal heart is generally integrated into the mid-trimester 
anomaly scan at 19-22 weeks gestational age. 
Most structural abnormalities of the heart do not lead to hydrops due to presence of fetal 
shunts (foramen ovale and arterial duct) and low resistance to systemic arterial blood flow 
related to the placental circulation. Fetal hydrops develops in the presence of failure of both 
ventricles. See Table 1 for a detailed list of structural cardiac abnormalities causing fetal 
hydrops. In virtually all cases of hydrops related to a cardiac abnormality the heart is 
enlarged and the degree of enlargement has been shown to correlated with the central 
venous pressure [73]. Those babies with a congenital cardiac malformation who develop 
fetal hydrops have an extremely poor prognosis with a mortality rate of 92% [9]. A 
proportion of those babies with structural cardiac malformations will be identified as having 




Fetal arrhythmias are detected in 2% of all pregnancies, which usually consist of isolated 
atrial ectopic beats [74]. Most fetuses with ectopic beats have an unremarkable course but 
a tachycardia may supervene in a small minority [75]. Tachycardias can lead to a low cardiac 
output state and non-immune fetal hydrops [74]. The most common types of tachycardia 
are supraventricular tachycardia (SVT) and atrial flutter. Ventricular tachycardia (VT), atrial 
fibrillation and chaotic atrial tachycardia are diagnosed rarely during fetal life. Fetal VT is 
most commonly torsades des pointes due to fetal long QT syndrome [76]. Where a fetus 
develops congestive cardiac failure secondary to arrhythmia there is an increased venous 
hydrostatic pressure leading to increased capillary permeability and shift of fluid into the 
interstitial spaces causing oedema. All tachycardias (HR>200180bpm) and bradycardias 
(HR<110bpm) can lead to non-immune fetal hydrops. 
Supraventricular tachycardia, the most common cause of fetal tachycardia (~70%), is an 
important cause of non-immune fetal hydrops, not least because it is treatable [77]. In 
postnatal life most cases of SVT will not persist beyond the first year.  Where there is 
significant fetal compromise, treatment consists of the transplacental administration of 
drugs such as digoxin, flecainide or sotalol.  
Non-immune fetal hydrops can occur as a result of other tachyarrhythmias such as atrial 
flutter and rarely ventricular tachycardia. 
Fetal bradyarrhythmias are less common and more difficult to treat. Sinus bradycardias are 
typically due to sinus node dysfunction, most commonly due to fetal long QT syndrome [78] 
or left atrial isomerism [78]. We have also seen fetal bradycardia causing hydrops due to the 
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autosomal recessive Jervell Lange-Nielson Syndrome caused by mutations in KCNQ1. 
Transient sinus bradycardia is frequently observed with probe pressure and resolves when 
this is removed. A subnormal ventricular rate can be due to multiple blocked atrial ectopic 
beats (typically resolve spontaneously) or 2nd or 3rd degree (complete) atrioventricular 
block. Complete heart block is most commonly due to maternal anti-Ro/anti–La antibodies 
or structural heart disease notably discordant AV atrioventricular connections or left atrial 
isomerism. Anti-Ro and anti-La antibodies can be transferred transplacentaly in mothers 
with systemic lupus erythematosus causing neonatal lupus and complete heart block in 2% 
of affected pregnancies [79]. Mothers carrying Anti-Ro and / or Anti -La antibodies who 
have had one fetus affected have an increased risk of 15-20% of subsequent pregnancies 
being affected by complete heart block.  Treatment of immune mediated complete heart 
block is controversial. In selected cases dexamethasone, salbutamol or intravenous 
immunoglobulin are used, but without trial evidence of efficacy. Mothers known to carry 
Anti-Ro/La antibodies may be treated with hydroxychloroquine which might reduce the 
incidence of heart block[80]. Another important cause of persistent fetal bradycardia is 
atrioventricular conduction blocks in which the development of non-immune fetal hydrops 
is a poor prognostic sign. 
6.3 Cardiomyopathies 
Fetal cardiomyopathies are rare accounting for up to 11% of all fetal cardiac presentations 
[81]. The cardiomyopathies can be divided into dilated, where there is dilatation and 
reduced ventricular function of one or both ventricles and hypertrophic, where there is 
concentric ventricular or septal thickening [82]. 
6.3.1 Dilated cardiomyopathy 
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Dilated cardiomyopathy (with dilatation and reduced ventricular function of one or both 
ventricles) is rare in fetal life. Sivasankaran et al. reported on 50 cases of fetal dilated 
cardiomyopathy collected over a 20-year period in a specialist fetal cardiology clinic[83] 
[83]. Of those 50 cases, two-thirds developed hydrops at some point. Causes were varied 
including genetic (largely inborn errors of metabolism), anaemia, infection, and associated 
renal and cardiac abnormalities. Overall survival for those fetuses that developed hydrops 
was just 18% (compared to a 50% survival in the non-hydropic group) [83]. 
6.3.2Hypertrophic cardiomyopathy 
Noonan syndrome (discussed in more detail in ‘single-gene disorders’ is associated with a 
prenatal onset of hypertrophic cardiomyopathy (HCM). There is some genotype-phenotype 
correlation with those individuals with mutations in RAF1 developing cardiomyopathy in 
56% of cases and those with mutations in RIT1 in 75% of cases, compared to PTPN11-related 
cardiomyopathy in 9% of cases and SOS1-related cardiomyopathy in 10% [84]. The 
development of hypertrophic cardiomyopathy may not be evident until the third trimester 
so that serial fetal echocardiography is indicated for pregnancies at risk.  
Barth Syndrome is an X-linked disorder of mitochondrial function and stability caused by 
mutations in TAZ [85]. Clinically the condition results in a dilated cardiomyopathy with 
endocardial fibroelastosis, which can lead to hydrops antenatally [86]. On fetal 
echocardiography, crypts are characteristically seen in the apex and free wall [82]. Those 
that survive may show growth retardation, proximal skeletal myopathy, neutropenia and 
organic aciduria [85,87]. 
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Hypertrophic cardiomyopathy has been associated with other inborn errors of metabolism. 
63% of patients with congenital disorders of glycosylation have been shown to develop 
HCM, although this is based in relatively small numbers [88]. 
6.4 High-output cardiac failure 
The majority of hydrops cases with high output cardiac failure will result from fetal anaemia, 
but here we detail some of the additional causes of fetal high-output cardiac states. 
6.4.1 High flow Arteriovenous Malformations 
Arteriovenous malformations (AVMs) cause fetal hydrops secondary to high output cardiac 
failure. Vascular malformations are typically seen in the lungs as pulmonary arteriovenous 
malformations [89]. In the brain both cerebral arteriovenous malformations and vein of 
Galen aneurysms leading to fetal hydrops[90,91] Hydrops is also reported in cases with large 
congenital cutaneous haemangiomas[92]. 
6.4.2 Sacrococcygeal teratomas 
Sacrococcygeal teratomas (SCTs) affect approximately 1 in 27,000 births [93]. SCTs appear 
as mixed echogenicity masses, which extend from the fetal sacrum, and those which grow 
rapidly and are highly vascular are associated with increased mortality [94]. The high 
vascularity can lead to high output cardiac failure and subsequent fetal hydrops. The 
development of fetal hydrops leads to a 3.4-fold increase in SCT related mortality [95]. 
When the fetus is noted to be in a high-output cardiac state, and at risk of developing 
hydrops, fetal therapy can be considered consisting of open fetal surgical debulking, shunt 
placement or radiofrequency ablation [94][82]. 
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6.4.3 Thyroid abnormalities 
It is well established that the use of antithyroid drugs can lead to congenital malformations. 
Shveiky (2004) reports a case of late-onset fetal hydrops in a woman taking propylthiouracil 
for Grave’s disease [96]. It is postulated that the non-immune fetal hydrops resulted from a 
high-output cardiac failure due to an arterio-venous shunt in the large fetal goitre present. 
Interestingly in the case, levothyroxine was administered into the amniotic fluid (200g per 
week for three weeks), which led to regression of the fetal hydrops and a reduction in the 
size of the fetal goitre, thus mitigating any potential peripartum dystocia or neonatal airway 
issues [96]. Additionally, exposure to maternal circulating autoantibodies to TSH receptors 
(Grave’s disease) can lead to fetal hyperthyroidism with fetal tachycardia, highly vascular 
goitre and cardiac failure resulting in fetal hydrops [97,98]. 
7. Non anaemic, with no primary space occupying or cardiac abnormality 
If cardiac developmental abnormality has been excluded as the primary cause, then there 
are several other underlying reasons for the fetal hydrops that can be considered, such as 
chromosome abnormalities, single gene disorders, gastrointestinal or urogenital 
malformations (Figure 3). 
7.1 Chromosome abnormalities 
Chromosome aneuploidies are frequently seen in the fetus with raised nuchal translucency. 
This may progress to fetal hydrops. Trisomy 21 (Down syndrome) affects 13 in 10,000 live 
births (data from the USA) [99]. Not all cases of Down syndrome develop fetal hydrops, 
which likely results from aberrant lymphatic development [100]. Other features of Down 
syndrome may be seen prenatally including duodenal atresia, sandal gap, absent nasal bone 
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and cardiac anomalies (e.g. endocardial cushion defects and septal wall defects). In the third 
trimester some babies with Down syndrome develop fetal hydrops as a result of a transient 
myeloproliferative disorder and associated anaemia as described [101]. 
Trisomy 18 (Edward Syndrome) and Trisomy 13 (Patau Syndrome) are also relatively 
frequently diagnosed in the context of fetal hydrops. Both are multisystem disorders with 
Edward syndrome characteristically recognised by the ultrasound demonstration of 
clenched hands and ‘rocker-bottom feet’. Midline defects are prominent in Patau syndrome 
with holoprosencephaly and cyclopia seen in addition to multisystem abnormalities. Fetal 
hydrops develops in 14% of fetuses with trisomy 18 and 3% of those with trisomy 13 [102]. 
Turner syndrome (45X0) is the commonest cause of genetic fetal hydrops [103]. Aside from 
significantly raised nuchal translucency and hydrops, renal malformations and congenital 
cardiac disease (most commonly coarctations of the aorta) are seen. In postnatal life 
individuals may have dysmorphism, short stature with mild learning difficulties and 
congenital four-limb lymphoedema which resolves during childhood (but may return) [104]. 
The presence of fetal hydrops in patients with Turner syndrome is a poor prognostic 
indicator within the region of 80-99% of affected fetuses suffering in-utero demise 
[105,106]. 
It is not unusual to find more complicated karyotype abnormalities in the context of non-
immune fetal hydrops. This can include duplications, deletions, insertions and inversions 
some of which cause well recognised post-natal syndromes such as Pallister-Kilian syndrome 
(mosaic tetrasomy 12p) and Di George syndrome (22q11 microdeletion) [107,108]. 
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The gold-standard for the diagnosis of fetal chromosome abnormalities is through invasive 
testing (amniocentesis or chorionic villus sampling). Most women with a pregnancy with 
trisomy 21 are identified as having a high-risk pregnancy based on first trimester screening, 
which combines the measurement of the fetal nuchal translucency with the maternal serum 
markers (Papp-A, free-beta HCG) [109]. 
Increasingly women are being tested using NIPT (Non-Invasive Prenatal Testing). From a 
simple maternal blood sample, a new highly sensitive and specific screening test can 
quantify fetal chromosome 21 fragments freely circulating in the maternal blood [110]. The 
test is also proving to be increasingly accurate for trisomies 13 and 18 and is now offered for 
other chromosome deletion syndromes (with significantly reduced sensitivity and 
specificity) [111]. 
7.2 Single Gene disorders 
The single-gene disorders associated with fetal hydrops can be divided into inborn errors of 
metabolism, haematological disorders, lymphatic disorders (including RASopathies), skeletal 
dysplasias, and a miscellaneous group. The pathogenesis of the hydrops in this group of 
multiple abnormality syndromes can be multi-factorial with cardiac, lymphatic and 
haematological abnormalities all contributory within the same single-gene disorder. 
It is important to recognise that almost any single-gene disorder, which presents with a 
severe phenotype in-utero, has been or may be identified as causing non-immune fetal 
hydrops. This is less the product of the specific genetic aberration but more due to the 
recognition that fetal hydrops is routinely observed in the decompensating fetus. This is 
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likely due to a vicious cycle of cardiac dysfunction, poor perfusion and imbalanced fluid 
homeostasis and portends an ominous prognosis. 
7.2.1 Lymphatic abnormalities 
Primary lymphatic anomalies may be caused by mutations in a number of genes [112]. Many 
of these disorders have been seen presenting antenatally with fetal hydrops. In addition, 
there is a group of syndromes (RASopathies and PIK3CA-related overgrowth syndromes) 
that have been grouped here owing to the associated fetal hydrops resulting from lymphatic 
malformation. 
Homozygous mutations in PIEZO1 cause generalised lymphatic dysplasia of Fotiou in 
postnatal life and can present prenatally as non-immune fetal hydrops [113]. The PIEZO1 
gene encodes a highly conserved, large transmembrane protein that is a mechanically 
activated cation channel [114]. Postnatally affected individuals, in addition to widespread 
lymphoedema, may have systemic complications including pulmonary lymphangiectasia, 
pleural effusions chylothoraces and pericardial effusions [104]. Autosomal dominant gain-
of-function mutations in PIEZO1 cause dehydrating hereditary stematocytosis which can 
also present with a severe fetal hydrops/ perinatal oedema phenotype[110] 
Heterozygous mutations in EPHB4 have been shown to cause non-immune fetal hydrops 
and with extensive fetal morbidity [115]. EPHB4 binds to Ephrin B2, a transmembrane 
protein, inducing a signalling cascade essential for the development of lymphatic vessel and 
valve formation during embryonic and neonatal life [115–117]. Survivors may develop 
lymphoedema and or varicose veins later in life [115]. 
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Hennekam syndrome was first described in 1989 in a series of related individuals with 
severe limb, genital and facial lymphoedema as well as poor growth, seizures and 
intellectual impairment [118]. One type of Hennekam syndrome is caused by pathogenic 
mutations in CCBE1 [119]. CCBE1 is crucial to lymphangiogenesis due to its role in 
lymphangioblast budding [120], and mutations have been shown to cause recurrent fetal 
hydrops [121,122]. Mutations in FAT4, ADAMTS3 and FBXL7 have also been implicated 
Hennekam Syndrome [123–125]. 
Heterozygous mutations in the gene FLT4 (VEGFR3) cause Milroy disease, which typically 
presents at birth, or soon after, with bilateral pedal oedema [126]. There have been rare 
reports of antenatal presentation of FLT4/VEGFR3 mutations, including fetuses affected by 
ascites, pleural effusions and limb oedema [127–129]. 
Lymphoedema-distichiasis is caused by pathogenic mutations in the forkhead transcription 
factor gene FOXC2 [16]. The syndrome is characterised by pubertal onset of lower limb 
lymphoedema and additional congenital abnormalities, namely distichiasis (aberrant growth 
of eyelashes). Other malformations are observed including varicose veins, cardiac defects, 
cleft palate, ptosis and spinal extradural cysts [130]. Cases of non-immune fetal hydrops 
with FOXC2 mutations are reported, but it is not a primary feature of the condition 
suggesting that affected cases may have genetic modifiers, which worsen the severity of the 
presentation [16,131,132]. 
7.2.2 The RASopathies 
The RASopathies are a group of disorders caused by germline mutations in crucial elements 
of the RAS/mitogen-activated protein kinase (MAPK) pathway, which controls cell 
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differentiation, proliferation and survival [133]. There is much phenotypic overlap in these 
disorders with most having variations on a recognisable pattern of facial dysmorphism, 
short stature and congenital heart disease. 
The RAS-MAPK pathway disorders are an important group to consider in relation to fetal 
hydrops, as they are recognised to present antenatally with raised nuchal translucency, 
hydrothorax or non-immune fetal hydrops as a result of aberrant lymphatic development 
[134]. 
In Noonan syndrome, approximately 50% of cases who present postnatally are found to 
have mutations in PTPN11 [135,136]. As we carry out increasing amounts of in-utero genetic 
sequencing, we may find that antenatal presentation correlates more strongly with a 
different Noonan-causing gene. It is reported that 59% of pregnancies affected by Noonan 
Syndrome show a consistent pattern of raised nuchal translucency, pleural effusions and 
non-immune fetal hydrops, as well as polyhydramnios and cardiac defects [137]. Absence of 
the ductus venosus has also been observed in approximately 50% of cases [137,138]. It is 
thought that the lymphatic abnormalities in fetuses with Noonan syndrome result from a 
disturbance in lymphatic endothelial differentiation due to diminished expression of the 
lymphatic markers PROX1 and Podoplanin and an increase in the vascular markers VEGF-A 
and Neuopilin-1 [139]. The fetal hydrops in Noonan syndrome is likely due to lymphatic 
malformation rather than congenital heart disease. 
There is some evidence of genotype-phenotype correlation within Noonan syndrome. 
Patients with RIT1 mutations have a much higher incidence of hypertrophic cardiomyopathy 
(see ‘cardiomyopathies’) (54%) but also perinatal abnormalities (100%), including raised 
nuchal translucency (67%), polyhydramnios (67%), fetal hydrops (38%), and pleural 
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effusions (62%) [84]. The diagnosis of Noonan syndrome during pregnancy can be 
enormously helpful. A persistently raised nuchal translucency is a strong predictor of 
Noonan syndrome[138] and is seen in postnatal life as the neck webbing typical of this 
condition. If the fetus does not develop significant cardiac compromise, these babies often 
survive and can go on to lead healthy lives, sometimes with minimal intellectual deficit. 
7.2.3 Inborn errors of metabolism (IEM) 
7.2.3.1 Lysosomal Storage disease (LSD) 
Most babies with IEM-related hydrops will have a lysosomal storage disease (LSD), 17 of 
which have been shown to cause non-immune fetal hydrops to date [140]. In a systematic 
review by Gimovsky et al. (2015), in 678 cases of non-immune fetal hydrops, 5.2% were 
diagnosed with an LSD during the pregnancy. Of those cases labelled as ‘idiopathic’, 17.4% 
were later diagnosed with an LSD on post-natal investigations [141]. Mucopolysaccharidosis 
type VII represented 20% of all LSD diagnoses, Gaucher was the next most frequent at 
17.1%, followed by GM1-gangliosidosis at 14.3% [141]. 
The non-immune fetal hydrops resulting from LSDs typically starts in the second trimester 
and may be associated with hepatosplenomegaly and ascites [142]. It is postulated that the 
fluid is accumulated due to venous obstruction secondary to visceromegaly resulting from 
abnormal accumulation of storage material [143]. 
7.2.3.2 Other Metabolic disorders 
The peroxisomal biosynthesis disorders, are an umbrella term for a spectrum of disorders 
ranging from the severe Zellweger syndrome, intermediate neonatal adrenoleukodystrophy 
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and mild Infantile Refsum disease [144]. These are recessively inherited disorders caused by 
mutations in the PEX genes, and there are rare reports of antenatal hydrops presentation in 
addition to varied, non-specific, dysmorphism [140,145]. 
Smith-Lemli-Opitz (SLO) is a recessively inherited multiple malformation syndrome caused 
by mutations in DHCR7 leading to deficiency of 7dehydrocholesterol reductase [146]. Fetal 
hydrops has been reported, possibly related to fetal akinesia (and lymphatic stasis) 
[147,148]. Individuals with SLO typically have microcephaly, characteristic facial 
dysmorphism, polydactyly, intellectual disability and autistic spectrum disorder [146,149]. 
Other inborn errors of metabolism associated with non-immune fetal hydrops include 
glycogenosis type IV, transaldolase deficiency, congenital disorders of glycosylation and 
citric acid cycle defects [88]. 
7.2.3.3 Prenatal diagnosis in suspected metabolic disorder 
Differentiating between inborn errors of metabolism on ultrasound and history alone is very 
challenging (although hepatosplenomegaly is a clue to LSDs). In recent clinical practise, we 
are able to undertake large gene panel or clinical exome sequencing (coding parts of DNA in 
a pre-determined ‘virtual’ panel of genes) in cases of suspected metabolic disorder. Exome 
testing may identify mutations in any of a large panel of genes associated with IEM related 
hydrops. Often, the knowledge of the metabolic diagnosis during the pregnancy allows for 
better prognostication and subsequent informed decision making regarding the pregnancy. 
In those babies, which survive to term and beyond, a diagnosis can prevent the need for a 




Sundrie-Arnaud et al. undertook a study of 46 cases with non-immune fetal hydrops, 
polyhydramnios associated with additional fetal anomaly or effusions for whom no 
explanation had been identified (via autopsy and standard genetic testing) [140]. DNA from 
all cases underwent Next Generation Sequencing (NGS) using a panel of 41 IEM genes. A 
causative mutation in a gene associated with IEM was found in 6 (13%) of cases [140]. 
 
7.2.4 Skeletal Dysplasias 
There are more than 450 skeletal dysplasias described in the literature [150]. Many of these 
can be diagnosed antenatally by ultrasound identification of short long bones, abnormal 
bone morphology, abnormal bony opacity (aberrant mineralisation) or additional or missing 
bones for that gestational age. The specific diagnosis can be particularly challenging 
prenatally and effort is made to differentiate those skeletal dysplasias, which are lethal from 
those which are not. This is information that is particularly useful to parents when making 
decisions about managing a pregnancy. Consideration must also be given to delivery as 
many skeletal dysplasia are complicated by fractures and the incidence of traumatic birth 
can be reduced with the decision to undertake a planned caesarean section. 
The prenatal ultrasound is usually the first indicator of skeletal dysplasia. The earlier in a 
pregnancy that short femurs (>2 SD below mean for gestational age) are identified the more 
likely that the skeletal dysplasia will be of a lethal type [151]. An estimation of lung volume 
is essential as lethality arise from pulmonary hypoplasia resulting in inadequate pulmonary 
surface area for effective respiratory exchange [152]. Other features predicative of a lethal 
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skeletal dysplasia are: decreased femur length to abdominal circumference ratio, visceral 
abnormalities, severe polyhydramnios and fetal hydrops [153]. 
Ultrasound examination alone is often sufficient to determine lethality, but will not provide 
a specific diagnosis in about a third of all cases [154]. Improvements in genetic technology 
have allowed an accurate molecular diagnosis of the specific type of skeletal dysplasia [155]. 
Where there are well delineated genotype-phenotype correlations knowledge of the 
specific mutation can provide useful information about the natural history of the disorder 
[156]. There is now the option to undertake highly accurate molecular diagnosis from free-
fetal DNA (Non-Invasive Prenatal Diagnosis/NIPD) for mutations in FGFR3 [157] (accounting 
for some of the most frequently occurring skeletal dysplasias). 
Many of the severe skeletal dysplasias seen antenatally are complicated by hydrops. The 
pathophysiology is not entirely clear. The development of non-immune fetal hydrops is 
likely secondary as a combination of different factors, including ineffective bony 
erythropoiesis (anaemia) and increased thoracic pressure causing lymphatic stasis [158]. 
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7.2.5 Other single gene syndromic causes. 
In postnatal life mutations in FOXP3 cause an X-linked immune dysregulation, 
polyendocrinopathy, enteropathy and autoimmunity (IPEX) syndrome. The FOXP3 protein 
plays a critical role in T Regulatory cell production and function and essentially affected 
patients have dysfunction of their TH1 lymphocytes [159] Whilst it is not a common cause of 
fetal hydrops there are multiple reports of hydrops in affected male fetuses[160,161]. Why 
the phenotype is so severe as to cause fetal hydrops in these cases remains unknown and 
the pathogenesis of the fetal hydrops is unclear. 
Kabuki Syndrome is a well-recognised multiple malformation syndrome characterised by 
intellectual impairment, facial dysmorphism, short stature, persistent fetal finger pads as 
well as cardiac, vertebral and renal malformations [162]. Mutations in KMT2D cause 
autosomal dominant Kabuki syndrome, but it is becoming clear that there is an emerging 
phenotype, distinct from classical Kabuki, that has a more severe fetal presentation 
[163,164]. It is not a common cause of fetal hydrops. 
7.3 Gastrointestinal malformation 
Gastrointestinal causes are included in most aetiology reports of non-immune fetal hydrops. 
However, they make up a small percentage of all cases and there are a limited number of 
case reports. Meconium peritonitis results from the rupture of the fetal bowel and the leak 
of meconium into the peritoneal space. The inflammation that ensues appears as 
calcifications on the fetal ultrasound and dilated bowel loops. It is seen more frequently in 
fetuses with cystic fibrosis although it is still a rare complication. Meconium peritonitis 
usually causes ascites, but this has been shown to cause a more severe presentation of 
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hydrops [165]. Any cause of bowel infarction and resultant fluid loss into the peritoneal 
cavity (stenosis, atresia, volvulus, peritoneal bands, imperforate anus, intussusception) can 
cause oedema as a result of the reduced vascular colloid osmotic pressure [9]. 
7.4 Urogenital malformation 
Urorectal septum malformation sequence (URSMS) leading to meconium peritonitis and 
non-immune fetal hydrops was first reported in 2006 [166]. Subsequently multiple papers 
looking at the aetiology of all fetal hydrops cases attribute a small percentage (2-3%) to 
‘urogenital malformations’, including prune-belly syndrome, renal agenesis, neonatal 
Bartter syndrome and cystic kidney disease [2,72,167–169]. Still, non-immune fetal hydrops 
is an unusual presentation of urogenital tract malformations. There is little published in the 
literature which explores the relationship between urogenital malformations and fetal 
hydrops, or which attempts to explain the pathophysiology of the oedema. 
7.5  Gestational Autoimmune Liver Disease/Neonatal hemochromatosis 
Gestational autoimmune liver disease (GALD) occurs when there is transplacental passage 
of maternal IgG antibodies to fetal liver antigens[170, 178]. The ensuing destruction of fetal 
hepatocytes leads to fetal liver failure with fibrosis and cirrhosis. As in post-natal liver 
failure, there is fetal hypoalbuminaemia [171], which is likely to cause reduce vascular 
colloid osmotic pressure and fluid shift into the interstitium. Diagnosis is confirmed by 
identification of non-hepatic siderosis. Antenatal therapy with high dose IVIG (Intravenous 





The ‘idiopathic’ group consists of cases where no cause for the fetal hydrops has been 
identified. In one recent multi-center study in the USA, 46% of cases of non-immune fetal 
hydrops remained undiagnosed after standard karyotype/chromosomal microarray plus 
exome analysis, with a further 9% with a suspected, but unconfirmed diagnoses [103]. A 
meta-analysis by Bellini’s group in 2015, reported a lower ‘idiopathic’ diagnosis rate in a 
large cohort (18.2%), although there was no standardisation of genetic testing of the 
assignation of ‘idiopathic’ among the 24 papers included in the metanalysis [158]. 
As prenatal exome sequencing becomes increasingly available and with further gene 
discovery, we expect the percentage of undiagnosed cases to reduce. We believe that a 
large portion of the idiopathic group will be found to have mutations in genes (known or 
unknown) associated with normal lymphatic development or inborn errors of metabolism. 
8.  Ballantyne Syndrome and Maternal Oedema 
In rare cases fetal hydrops can progress to oedema of the placenta and maternal oedema. 
This triad of symptoms has been coined Mirror syndrome (as it ‘mirrors’ the fetal state) and 
has been eponymously named after John William Ballantyne who first described the 
condition in 1892[173]. The exact incidence of this condition is unknown but it has been 
estimated to affect approximately 1 in 3000 pregnancies, although it is likely 
underdiagnosed[174,175]. One systematic review of 2010 found 56 case reports in the 
published literature and of those, maternal hypertension was present in 57-78% of cases, 
proteinuria in 20-56% with in-utero fetal death occurring in 56% of cases[176]. Fetal survival 
appears to be improved by correction of fetal anaemia and induction of labour[177]. It is 
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important to recognise Ballantyne syndrome as a differential diagnosis for preeclampsia as 
maternal oedema, hypertension, rapid weight gain, dyspnoea and albuminaemia 
characterise both conditions[175]. Ballantyne syndrome can be differentiated by the 
presence of a dilutional anaemia with a low maternal haematocrit[178]. 
 
9. Conclusions 
Making a diagnosis in cases of fetal hydrops is pivotal to providing the parents with accurate 
information about the prognosis, both in the context of the pregnancy and in post-natal life, 
and recurrence risk. In the first trimester fetal hydrops is almost always associated with 
lethal chromosome abnormalities. From the second trimester the presence or absence of 
fetal anaemia can guide the clinician’s investigatory pathway as outlined in Figure 3. 
Ultrasound imaging findings can identify thoracic space occupying lesions that cause a 
mechanical lymphatic obstruction or evidence of cardiac or vascular structural 
abnormalities, which cause hydrops secondary to increased cardiac work. Where fetal 
anaemia and cardiothoracic abnormalities have been excluded, single-gene disorders are 
the largest remaining group. Ultrasound features can be highly suggestive of specific single-
gene disorders (especially skeletal dysplasias and metabolic disorders). Genetic sequencing 
via whole exomes will improve our diagnostic yield in these disorders but a significant 
proportion will remain undiagnosed. 
Expert Opinion 
 
The identification of non-immune fetal hydrops is a poor prognostic factor in a pregnancy 
and often indicates a decompensating fetus. Due to the multitude of potential causes 
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investigations must be prioritised based on ultrasound features and clues to underlying 
pathophysiology. 
We have been in a position to provide a limited clinical exome sequencing service to these 
patients and have found that families find it helpful to have a molecular diagnosis when 
making difficult decisions about management of an affected pregnancy. We have found the 
diagnostic yield to be particularly high in cases of fetal abnormality with the addition of fetal 
hydrops (as yet unpublished data). In one case we have also been able to put in place early 
neonatal enzyme replacement therapy due to having made an accurate in-utero diagnosis. 
In the future, as genetic sequencing becomes more routine, owing to increased affordability 
and rapid turn-around times, genetic testing will feature more prominently and earlier in 
the investigation process. It is foreseeable that, in the not too distant future, genomic 
testing will be undertaken from maternal blood as early as 9 weeks gestation, which will 
look not only for single gene disorders but also chromosome aneuploidies and copy number 
variants. Prenatal exome sequencing can now be undertaken in a matter of a few weeks and 
we expect turn-around times to continue to reduce, making this a primary investigation in 
cases of fetal hydrops. 
However, further research is needed to identify casual genes. In the process of this research 
we will also expand the phenotype of genes, which cause well described postnatal 
phenotypes, into the prenatal setting. There are significant challenges to variant 
interpretation as assigning pathogenicity to a newly discovered variant is particularly 




An early genetic diagnosis is valuable as it ends the ‘diagnostic odyssey’ thus preventing the 
need for continued invasive investigations throughout the rest of the pregnancy and post-
natal life [80]. The next decade will dawn the era of precision medicine whereby a molecular 




Dr Esther Dempsey is supported by the British Heart Foundation (FS/18/78/33932). 
Declaration of interest 
The authors declare that there is no conflict of interest regarding the publication of this 
article. 
Acknowledgments 
Prof. John Simpson acknowledges support by the Department of Health through the 
National Institute for Health Research comprehensive Biomedical Research Centre award to 
Guy’s and St Thomas’ National Health Service Foundation Trust in partnership with King’s 




[1] HEINONEN S, RYYNÄNEN M, KIRKINEN P. Etiology and outcome of second trimester non‐
immunologic fetal hydrops. Acta Obstet Gyn Scan. 2000;79:15–18.  
 
[2] Derderian CS, Jeanty C, Fleck SR, et al. The many faces of hydrops. J Pediatr Surg. 
2015;50:50–54.  
 
[3] Fukushima K, Morokuma S, Fujita Y, et al. Short-term and long-term outcomes of 214 
cases of non-immune hydrops fetalis. Early Hum Dev. 2011;87:571–575.  
 
[4] Levick J. Circulation of fluid between plasma, interstitium and lymph.11 :188–219. In: An 
Introduction to Cardiovascular Physiology. 5th Edition. 2010 Hodder Arnold. London 
 
[5] Randenberg A. Nonimmune Hydrops Fetalis Part I: Etiology and Pathophysiology. 
Neonatal Netw. 2010;29:281-295(15).  
 
[6] Levick RJ, Michel CC. Microvascular fluid exchange and the revised Starling principle. 
Cardiovasc Res. 2010;87:198–210.  
 
[7] Hellmund A, Berg C, Geipel A, et al. Prenatal diagnosis of fetal akinesia deformation 
sequence (FADS): a study of 79 consecutive cases. Arch Gynecol Obstet. 2016;294:697–707.  
 
[8] Norton ME, Chauhan SP, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical 
39 
 
Guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol. 2014;212:127–139.  
 
[9] Désilets V, Bie I, Audibert F. No. 363-Investigation and Management of Non-immune 
Fetal Hydrops. J Obstetrics Gynaecol Can. 2018;40:1077–1090.  
 
[10] Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood 
Rev. 2000;14:44–61.  
 
[11] Fung K, Eason E, Crane J, et al. Prevention Of RH Alloimmunization This guideline has 
been reviewed by the Maternal-Fetal Medicine Committee and the Genetics Committee, 
with input from the Rh Program of Nova Scotia, and approved by the Executive and Council 
of the Society of Obstetricians and Gynaecologists of Canada. J Obstetrics Gynaecol Can. 
2003;25:765–773.  
 
[12] Regan F, Lees C, Jones B, et al. Prenatal Management of Pregnancies at Risk of Fetal 
Neonatal Alloimmune Thrombocytopenia (FNAIT). Bjog Int J Obstetrics Gynaecol. 
2019;126:e173–e185.  
 
[13] Kjær M, Bertrand G, Bakchoul T, et al. Maternal HPA‐1a antibody level and its role in 
predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic 
review. Vox Sang. 2019;114:79–94.  
 
[14] Kamphuis M, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal 





[15] Jain V, Clarke G, Russell L, et al. A Case of Alloimmune Thrombocytopenia, Hemorrhagic 
Anemia-Induced Fetal Hydrops, Maternal Mirror Syndrome, and Human Chorionic 
Gonadotropin–Induced Thyrotoxicosis. Am J Perinatology Reports. 2013;03:041–044.  
 
[16] Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a Forkhead Family 
Transcription Factor, Are Responsible for the Hereditary Lymphedema-Distichiasis 
Syndrome. Am J Hum Genetics. 2000;67:1382–1388.  
 
[17] Wylie BJ, D’Alton ME. Fetomaternal Hemorrhage. Obstetrics Gynecol. 2010;115:1039–
1051.  
 
[18] Kleihauer E, Braun H, Betke K. Demonstration von fetalem Hämoglobin in den 
Erythrocyten eines Blutausstrichs. Klin Wochenschr. 1957;35:637–638.  
 
[19] Rubod C, Houfflin V, Belot F, et al. Successful in utero Treatment of Chronic and 
Massive Fetomaternal Hemorrhage with Fetal Hydrops. Fetal Diagn Ther. 2006;21:410–413.  
 
[20] Enders G, Biber M. Parvovirus B19 infections in pregnancy. Behr Inst Mitt. 1990;74–78.  
 
[21] Jensen I, Thorsen P, Jeune B, et al. An epidemic of parvovirus B19 in a population of 
3596 pregnant women: a study of sociodemographic and medical risk factors. Bjog Int J 




[22] Valeur-Jensen A, Pedersen CB, Westergaard T, et al. Risk Factors for Parvovirus B19 
Infection in Pregnancy. Jama. 1999;281:1099–1105.  
 
[23] Yageashi N, Niinuma T, Chisaka H, et al. The incidence of, and factors leading to, 
parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and 
meta-analysis. J Infection. 1998;37:28–35.  
 
[24] Chisaka H, Morita E, Yaegashi N, et al. Parvovirus B19 and the pathogenesis of anaemia. 
Rev Med Virol. 2003;13:347–359.  
 
[25] de Jong E, Walther F, Kroes A, et al. Parvovirus B19 infection in pregnancy: new insights 
and management. Prenatal Diag. 2011;31:419–425.  
 
[26] Giorgio E, Oronzo M, Iozza I, et al. Parvovirus B19 during pregnancy: a review. J Prenat 
Medicine. 2010;4:63–66.  
 
[27] Ornoy A, Ergaz Z. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth 
Defects Res. 2017;109:311–323.  
 
[28] Xiong Y, Tan J, Liu Y, et al. The risk of maternal parvovirus B19 infection during 
pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis. J Clin 




[29] Barron SD, Pass RF. Infectious causes of hydrops fetalis. Semin Perinatol. 1995;19:493–
501.  
 
[30] Sarno M, Sacramento GA, Khouri R, et al. Zika Virus Infection and Stillbirths: A Case of 
Hydrops Fetalis, Hydranencephaly and Fetal Demise. Plos Neglect Trop D. 
2016;10:e0004517.  
 
[31] Fuchs F, Michaux K, Rousseau C, et al. Syphilis Infection: An Uncommon Etiology of 
Infectious Nonimmune Fetal Hydrops with Anemia. Fetal Diagn Ther. 2016;39:74–77.  
 
[32] Schild R, Bald R, Plath H, et al. Intrauterine management of fetal parvovirus B19 
infection. Ultrasound Obst Gyn. 1999;13:161–166.  
 
[33] Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human 
parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenatal Diag. 
2004;24:513–518.  
 
[34] Bamberg C, Hecher K. Update on twin-to-twin transfusion syndrome. Best Pract Res Cl 
Ob. 2019;  
 
[35] Kontopoulos E, Chmait RH, Quintero RA. Twin-to-Twin Transfusion Syndrome: 
Definition, Staging, and Ultrasound Assessment. Twin Res Hum Genet. 2016;19:175–183.  
 
[36] Quintero RA, Morales WJ, Allen MH, et al. Staging of Twin-Twin Transfusion Syndrome. 
43 
 
J Perinatol. 1999;19:7200292.  
 
[37] Rossi CA, Vanderbilt D, Chmait RH. Neurodevelopmental Outcomes After Laser Therapy 
for Twin–Twin Transfusion Syndrome. Obstetrics Gynecol. 2011;118:1145–1150.  
 
[38] Arcasoy MO, Gallagher PG. Hematologic disorders and nonimmune hydrops fetalis. 
Semin Perinatol. 1995;19:502–515.  
 
[39] Chui D, Waye J. Hydrops fetalis caused by alpha-thalassemia: an emerging health care 
problem. Blood. 1998;91:2213–2222.  
 
[40] Chan V, Chan T, Liang S, et al. Hydrops fetalis due to an unusual form of Hb H disease. 
Blood. 1985;66:224–228.  
 
[41] Bernini LF, Harteveld CL. 2 α-Thalassaemia. Baillière’s Clin Haematol. 1998;11:53–90.  
 
[42] Clark B, Thein S. Molecular diagnosis of haemoglobin disorders. Clin Laboratory 
Haematol. 2004;26:159–176.  
 
[43] Diamond L, Blackfan K. Hypoplastic anaemia. Am J Dis Children. 1938; 56;464-467. 
 
[44] Aspesi A, Betti M, Sculco M, et al. A functional assay for the clinical annotation of 





[45] Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations 
resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122:2439–2443.  
 
[46] Gripp KW, Curry C, Olney A, et al. Diamond–Blackfan anemia with mandibulofacial 
dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28. Am J Med 
Genet A. 2014;164:2240–2249.  
 
[47] Vlachos A, Blanc L, Lipton JM. Diamond Blackfan anemia: a model for the translational 
approach to understanding human disease. Expert Rev Hematol. 2014;7:359–372.  
 
[48] Noel C. Diamond–Blackfan anemia RPL35A: a case report. J Medical Case Reports. 
2019;13:185.  
 
[49] Mclennan Ac, Chitty Ls, Rissik J, et al. Prenatal diagnosis of Blackfan–Diamond 
syndrome: case report and review of the literature. Prenatal Diag. 1996;16:349–353.  
 
[50] Wlodarski MW, Costa L, O’Donohue M-F, et al. Recurring mutations in RPL15 are linked 
to hydrops fetalis and treatment independence in Diamond-Blackfan anemia. 
Haematologica. 2018;103:haematol.2017.177980.  
 
[51] Tamary H, Dgany O, Proust A, et al. Clinical and molecular variability in congenital 




[52] Liu S, Liu Y-N, Zhen L, et al. Fetal-onset congenital dyserythropoietic anemia type 1 due 
to CDAN1 mutations presenting as hydrops fetalis. Pediatr Hemat Oncol. 2019;35:447–450.  
 
[53] Chin H-L, Lee L, Koh P. Fetal-onset Congenital Dyserythropoietic Anemia Type 1 due to a 
Novel Mutation With Severe Iron Overload and Severe Cholestatic Liver Disease. J Pediatric 
Hematology Oncol. 2017;41:e51–e53.  
 
[54] Hasle H, Clemmensen I, Mikkelsen M. Risks of leukaemia and solid tumours in 
individuals with Down’s syndrome. Lancet. 2000;355:165–169.  
 
[55] Bhatnagar N, Nizery L, Tunstall O, et al. Transient Abnormal Myelopoiesis and AML in 
Down Syndrome: an Update. Curr Hematol Malig R. 2016;11:333–341.  
 
[56] Wechsler J, Greene M, vitt MA, et al. Acquired mutations in GATA1 in the 
megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–152.  
 
[57] Nikolaev SI, Santoni F, Vannier A, et al. Exome sequencing identifies putative drivers of 
progression of transient myeloproliferative disorder to AMKL in infants with Down 
syndrome. Blood. 2013;122:554–561.  
 
[58] Tamblyn J, Norton A, Spurgeon L, et al. Prenatal therapy in transient abnormal 
myelopoiesis: a systematic review. Archives Dis Child - Fetal Neonatal Ed. 2016;101:67.  
 
[59] Watanabe K. Recent advances in the understanding of transient abnormal myelopoiesis 
46 
 
in Down syndrome. Pediatr Int. 2019;61:222–229.  
 
[60] Okamura T, Washio Y, Yoshimoto J, et al. Exchange Transfusion and Cytarabine for 
Transient Abnormal Myelopoiesis in Hydrops Fetalis. Acta Med Okayama. 2019;73:181–188.  
 
[61] Gajewska-Knapik K, Impey L. Congenital lung lesions: Prenatal diagnosis and 
intervention. Semin Pediatr Surg. 2015;24:156–159.  
 
[62] Witlox RS, Lopriore E, Oepkes D. Prenatal interventions for fetal lung lesions. Prenatal 
Diag. 2011;31:628–636.  
 
[63] Cavoretto P, Molina F, Poggi S, et al. Prenatal diagnosis and outcome of echogenic fetal 
lung lesions. Ultrasound Obst Gyn. 2008;32:769–783.  
 
[64] Peyce D. Lower accessory pulmonary artery with intralobar sequestration of lung: A 
Report of seven cases. J Pathology Bacteriol. 1946;58:457–467.  
 
[65] Sepulveda W. Perinatal Imaging in Bronchopulmonary Sequestration. J Ultras Med. 
2009;28:89–94.  
 
[66] Carrilho M, Tonni G, Júnior E. Fetal cardiac tumors: prenatal diagnosis and outcomes. 
Rev Bras Cir Cardiov. 2015;30:VI–VII.  
 




[68] Chao A, Chao A, Wang T, et al. Outcome of antenatally diagnosed cardiac 
rhabdomyoma: case series and a meta‐analysis. Ultrasound Obst Gyn. 2008;31:289–295.  
 
[69] Yuan S-M. Fetal Primary Cardiac Tumors During Perinatal Period. Pediatrics Neonatol. 
2017;58:205–210.  
 
[70] Steffensen TS, Quintero RA, Kontopoulos EV, et al. MASSIVE PERICARDIAL EFFUSION 
TREATED WITH IN UTERO PERICARDIOAMNIOTIC SHUNT IN A FETUS WITH 
INTRAPERICARDIAL TERATOMA. Fetal Pediatr Pathol. 2009;28:216–231.  
 
[71] Grebille A, Mitanchez D, Benachi A, et al. Pericardial teratoma complicated by hydrops: 
successful fetal therapy by thoracoamniotic shunting. Prenatal Diag. 2003;23:735–739.  
 
[72] Bellini C, Hennekam R, Fulcheri E, et al. Etiology of nonimmune hydrops fetalis: A 
systematic review. Am J Med Genet A. 2009;149A:844–851.  
 
[73] Johnson P, Maxwell D, Tynan M, et al. Intracardiac pressures in the human fetus. Heart. 
2000;84:59.  
 
[74] Bravo-Valenzuela N, Rocha L, Nardozza L, et al. Fetal cardiac arrhythmias: Current 
evidence. Ann Pediatric Cardiol. 2018;11:148.  
 
[75] Simpson JM, Milburn A, Yates RW, et al. Outcome of Intermittent Tachyarrhythmias in 
48 
 
the Fetus. Pediatr Cardiol. 1997;18:78–82.  
 
[76] Simpson J. Impact of fetal echocardiography. Ann Pediatric Cardiol. 2009;2:41–50.  
 
[77] Krapp M, Kohl T, Simpson J, et al. Review of diagnosis, treatment, and outcome of fetal 
atrial flutter compared with supraventricular tachycardia. Heart. 2003;89:913.  
 
[78] Ishikawa S, Yamada T, Kuwata T, et al. Fetal Presentation of Long QT Syndrome – 
Evaluation of Prenatal Risk Factors: A Systematic Review. Fetal Diagn Ther. 2013;33:1–7.  
 
[79] de Jesus G, Mendoza-Pinto C, de Jesus N, et al. Understanding and Managing Pregnancy 
in Patients with Lupus. Autoimmune Dis. 2015;2015:943490.  
 
[80] Marshall DA, MacDonald KV, Heidenreich S, et al. The value of diagnostic testing for 
parents of children with rare genetic diseases. Genet Med. 2019;1–9.  
 
[81] Mongiovi M, Fesslova V, Fazio G, et al. Diagnosis and Prognosis of Fetal 
Cardiomyopathies: A Review. Curr Pharm Design. 2010;16:2929–2934.  
 
[82] Davey B, Szwast A, Rychik J. Diagnosis and management of heart failure in the fetus. 
Minerva Pediatr. 2012;64:471–492.  
 
[83] Sivasankaran S, Sharland GK, Simpson JM. Dilated cardiomyopathy presenting during 




[84] Yaoita M, Niihori T, Mizuno S, et al. Spectrum of mutations and genotype–phenotype 
analysis in Noonan syndrome patients with RIT1 mutations. Hum Genet. 2016;135:209–222.  
 
[85] Clarke SL, Bowron A, Gonzalez IL, et al. Barth syndrome. Orphanet J Rare Dis. 2013;8:23.  
 
[86] Steward C, Newbury‐Ecob R, Hastings R, et al. Barth syndrome: an X‐linked cause of 
fetal cardiomyopathy and stillbirth. Prenatal Diag. 2010;30:970–976.  
 
[87] Barth P, den Bogert VC, Bolhuis P, et al. X-linked cardioskeletal myopathy and 
neutropenia (Barth syndrome): Respiratory-chain abnormalities in cultured fibroblasts. J 
Inherit Metab Dis. 1996;19:157–160.  
 
[88] Makhamreh MM, Cottingham N, Ferreira CR, et al. Non‐Immune Hydrops Fetalis and 
Congenital Disorders of Glycosylation: A Systematic Literature Review. J Inherit Metab Dis. 
2019;  
 
[89] Heling K ‐S., Tennstedt C, Göldner B, et al. Prenatal diagnosis of intrapulmonary 
arteriovenous malformation: sonographic and pathomorphological findings. Ultrasound 
Obst Gyn. 2002;19:514–517.  
 
[90] Godfrey ME, Tworetzky W, Morash D, et al. Cardiac Findings in the Fetus with Cerebral 





[91] Marinaş M, Mindrilă I, Zorilă G, et al. A Severe Case of Aneurysmal Malformation of the 
Vein of Galen, Cardiac Failure and Intrauterine Fetal Death. Curr Heal Sci J. 2018;44:76–79.  
 
[92] Darouich S, Bellamine H, Mkaouar L, et al. Congenital Large Cutaneous Hemangioma 
with Arteriovenous and Arterioarterial Malformations: A Novel Association. Fetal Pediatr 
Pathol. 2019;38:1–6.  
 
[93] Swamy R, Embleton N, Hale J. Sacrococcygeal teratoma over two decades: Birth 
prevalence, prenatal diagnosis and clinical outcomes. Prenatal Diag. 2008;28:1048–1051.  
 
[94] Wenstrom KD, Carr SR. Fetal Surgery. Obstetrics Gynecol. 2014;124:817–835.  
 
[95] Akinkuotu AC, Coleman A, Shue E, et al. Predictors of poor prognosis in prenatally 
diagnosed sacrococcygeal teratoma: A multiinstitutional review. J Pediatr Surg. 
2015;50:771–774.  
 
[96] Yanai N, Shveiky D. Fetal hydrops, associated with maternal propylthiouracil exposure, 
reversed by intrauterine therapy. Ultrasound Obst Gyn. 2004;23:198–201.  
 
[97] Kazakou P, Theodora M, Kanaka-Gantenbein C, et al. Fetal hyperthyroidism associated 





[98] King J, Lachica R, Lee RH, et al. Diagnosis and Management of Hyperthyroidism in 
Pregnancy. Obstet Gynecol Surv. 2016;71:675–685.  
 
[99] de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and 
elective terminations with Down syndrome in the United States. Am J Med Genet A. 
2015;167:756–767.  
 
[100] Bekker MN, van den Akker NM, de Mooij YM, et al. Jugular Lymphatic 
Maldevelopment in Turner Syndrome and Trisomy 21: Different Anomalies Leading to 
Nuchal Edema. Reprod Sci. 2008;15:295–304.  
 
[101] Anuk D, Tarcan A, Alioglu B, et al. Hydrops fetalis in a neonate with down syndrome, 
transient myeloproliferative disorder and hepatic fibrosis. Fetal Pediatr Pathol. 
2009;26:223–228.  
 
[102] Kroes I, Janssens S, Defoort P. Ultrasound features in trisomy 13 (Patau syndrome) and 
trisomy 18 (Edwards syndrome) in a consecutive series of 47 cases. Facts Views Vis Obgyn. 
2014;6:245–249.  
 
[103] Sparks TN, Thao K, Lianoglou BR, et al. Nonimmune hydrops fetalis: identifying the 
underlying genetic etiology. Genet Med. 2019;21:1339–1344.  
 





[105] Surerus E, Huggon I, Allan L. Turner’s syndrome in fetal life. Ultrasound Obst Gyn. 
2003;22:264–267.  
 
[106] Brown B. The ultrasonographic features of nonimmune hydrops fetalis: a study of 30 
successive patients. Can Assoc Radiologists J J L’association Can Des Radiologistes. 
1986;37:164–168.  
 
[107] Libotte F, Bizzoco D, Gabrielli I, et al. Pallister–Killian syndrome: Cytogenetics and 
molecular investigations of mosaic tetrasomy 12p in prenatal chorionic villus and in 
amniocytes. Strategy of prenatal diagnosis. Taiwan J Obstetrics Gynecol. 2016;55:863–866.  
 
[108] Machlitt A, Tennstedt C, Körner H, et al. Prenatal diagnosis of 22q11 microdeletion in 
an early second-trimester fetus with conotruncal anomaly presenting with increased nuchal 
translucency and bilateral intracardiac echogenic foci. Ultrasound Obstetrics Gynecol. 
2002;19:510–513.  
 
[109] Public Health England. NHS Fetal Anomaly Screening Programme; Public Health 
England Publications. 2018 
 
[110] Lo D, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and 
serum. Lancet. 1997;350:485–487.  
 
[111] Hu H, Wang L, Wu J, et al. Noninvasive prenatal testing for chromosome aneuploidies 
53 
 
and subchromosomal microdeletions/microduplications in a cohort of 8141 single 
pregnancies. Hum Genomics. 2019;13:14.  
 
[112] Connell F, Gordon K, Brice G, et al. The classification and diagnostic algorithm for 
primary lymphatic dysplasia: an update from 2010 to include molecular findings. Clin Genet. 
2013;84:303–314.  
 
[113] Fotiou E, Martin-Almedina S, Simpson MA, et al. Novel mutations in PIEZO1 cause an 
autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. Nat 
Commun. 2015;6:8085.  
 
[114] Coste B, Mathur J, Schmidt M, et al. Piezo1 and Piezo2 Are Essential Components of 
Distinct Mechanically Activated Cation Channels. Science. 2010;330:55–60.  
 
[115] Martin-Almedina S, Martinez-Corral I, Holdhus R, et al. EPHB4 kinase–inactivating 
mutations cause autosomal dominant lymphatic-related hydrops fetalis. J Clin Invest. 
2016;126:3080–3088.  
 
[116] Li D, Wenger TL, Seiler C, et al. Pathogenic variant in EPHB4 results in central 
conducting lymphatic anomaly. Hum Mol Genet. 2018;27:3233–3245.  
 
[117] Zhang G, Brady J, Liang W-C, et al. EphB4 forward signalling regulates lymphatic valve 




[118] Hennekam R, Geerdink R, Hamel B, et al. Autosomal recessive intestinal 
lymphangiectasia and lymphedema, with facial anomalies and mental retardation. Am J 
Med Genet. 1989;34:593–600.  
 
[119] Alders M, Hogan BM, Gjini E, et al. Mutations in CCBE1 cause generalized lymph vessel 
dysplasia in humans. Nat Genet. 2009;41:1272–1274.  
 
[120] Hogan BM, Bos FL, Bussmann J, et al. ccbe1 is required for embryonic 
lymphangiogenesis and venous sprouting. Nat Genet. 2009;41:396–398.  
 
[121] Melber DJ, Andreasen TS, Mao R, et al. Novel mutation in CCBE 1 as a cause of 
recurrent hydrops fetalis from Hennekam lymphangiectasia‐lymphedema syndrome‐1. Clin 
Case Reports. 2018;6:2358–2363.  
 
[122] Connell F, Kalidas K, Ostergaard P, et al. Linkage and sequence analysis indicate that 
CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet. 
2010;127:231–241.  
 
[123] Alders M, Al-Gazali L, Cordeiro I, et al. Hennekam syndrome can be caused by FAT4 
mutations and be allelic to Van Maldergem syndrome. Hum Genet. 2014;133:1161–1167.  
 
[124] Brouillard P, Dupont L, Helaers R, et al. Loss of ADAMTS3 activity causes Hennekam 




[125] Boone PM, Paterson S, Mohajeri K, et al. Biallelic mutation of FBXL7 suggests a novel 
form of Hennekam syndrome. Am J Med Genet A. 2019; 182(1):189-194. 
 
[126] Brice G, Child A, Evans A, et al. Milroy disease and the VEGFR-3 mutation phenotype. J 
Med Genet. 2005;42:98.  
 
[127] Boudon E, Levy Y, Abossolo T, et al. Antenatal presentation of hereditary lymphedema 
type I. Eur J Med Genet. 2015;58:329–331.  
 
[128] Daniel‐Spiegel E, Ghalamkarpour A, Spiegel R, et al. Hydrops fetalis: an unusual 
prenatal presentation of hereditary congenital lymphedema. Prenatal Diag. 2005;25:1015–
1018.  
 
[129] Ghalamkarpour A, Morlot S, Raas‐Rothschild A, et al. Hereditary lymphedema type I 
associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin 
Genet. 2006;70:330–335.  
 
[130] Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in 
lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 
16q24. J Med Genet. 2002;39:478.  
 
[131] Sargent C, Bauer J, Khalil M, et al. A five generation family with a novel mutation in 
FOXC2 and lymphedema worsening to hydrops in the youngest generation. Am J Med Genet 




[132] Ghalamkarpour A, Debauche C, Haan E, et al. Sporadic In Utero Generalized Edema 
Caused by Mutations in the Lymphangiogenic Genes VEGFR3 and FOXC2. J Pediatrics. 
2009;155:90–93.  
 
[133] Aoki Y, Niihori T, Inoue S, et al. Recent advances in RASopathies. J Hum Genet. 
2015;61:33–39.  
 
[134] Joyce S, Gordon K, Brice G, et al. The lymphatic phenotype in Noonan and 
Cardiofaciocutaneous syndrome. Eur J Hum Genet. 2015;24:690–696.  
 
[135] Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 Mutations in Noonan Syndrome: 
Molecular Spectrum, Genotype-Phenotype Correlation, and Phenotypic Heterogeneity. Am J 
Hum Genetics. 2002;70:1555–1563.  
 
[136] Bouchikhi I, Belhassan K, Moufid F, et al. Noonan syndrome-causing genes: Molecular 
update and an assessment of the mutation rate. Int J Pediatrics Adolesc Medicine. 
2016;3:133–142.  
 
[137] Staboulidou I, Pereira S, de Cruz J, et al. Prevalence and Outcome of Absence of 
Ductus Venosus at 11+0 to 13+6 Weeks. Fetal Diagn Ther. 2011;30:35–40.  
 
[138] Vigneswaran TV, Homfray T, Allan LD, et al. Persistently elevated nuchal translucency 




[139] de Mooij YM, van den Akker NM, Bekker MN, et al. Aberrant lymphatic development 
in euploid fetuses with increased nuchal translucency including Noonan syndrome. Prenatal 
Diag. 2011;31:159–166.  
 
[140] Sudrié-Arnaud B, Marguet F, Patrier S, et al. Metabolic causes of nonimmune hydrops 
fetalis: A next-generation sequencing panel as a first-line investigation. Clin Chim Acta. 
2018;481:1–8.  
 
[141] Gimovsky AC, Luzi P, Berghella V. Lysosomal storage disease as an etiology of 
nonimmune hydrops. Am J Obstet Gynecol. 2015;212:281–290.  
 
[142] Vianey-Saban C, Acquaviva C, Cheillan D, et al. Antenatal manifestations of inborn 
errors of metabolism: biological diagnosis. J Inherit Metab Dis. 2016;39:611–624.  
 
[143] Sheth J, Mistri M, Shah K, et al. JIMD Reports, Volume 35. 2016;47–52.  
 
[144] Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the 
Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and 
treatment guidelines. Mol Genet Metab. 2016;117:313–321.  
 
[145] Dursun A, Gucer S, Ebberink M, et al. Zellweger syndrome with unusual findings: non-
immune hydrops fetalis, dermal erythropoiesis and hypoplastic toe nails. J Inherit Metab 




[146] Bianconi SE, Cross JL, Wassif CA, et al. Pathogenesis, epidemiology, diagnosis and 
clinical aspects of Smith–Lemli–Opitz syndrome. Expert Opin Orphan D. 2015;3:267–280.  
 
[147] Maymon R, Ogle R, Chitty L. Smith–Lemli–Opitz syndrome presenting with persisting 
nuchal oedema and non‐immune hydrops. Prenatal Diag. 1999;19:105–107.  
 
[148] Putnam AR, Szakacs JG, Opitz JM, et al. Prenatal death in Smith–Lemli–Opitz/RSH 
syndrome. Am J Med Genet A. 2005;138A:61–65.  
 
[149] Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital 
anomalies. J Pediatrics. 1964;64:210–217.  
 
[150] Warman ML, Cormier‐Daire V, Hall C, et al. Nosology and classification of genetic 
skeletal disorders: 2010 revision. Am J Med Genet A. 2011;155:943–968.  
 
[151] Milks KS, Hill LM, Hosseinzadeh K. Evaluating skeletal dysplasias on prenatal 
ultrasound: an emphasis on predicting lethality. Pediatr Radiol. 2017;47:134–145.  
 
[152] Barros C, de Rezende G, Júnior E, et al. Prediction of lethal pulmonary hypoplasia by 
means fetal lung volume in skeletal dysplasias: a three-dimensional ultrasound assessment. 
J Maternal-fetal Neonatal Medicine. 2015;29:1–6.  
 
[153] Krakow D, Lachman RS, Rimoin DL. Guidelines for the prenatal diagnosis of fetal 
59 
 
skeletal dysplasias. Genet Med. 2009;11:127.  
 
[154] Parilla BV, Leeth EA, Kambich MP, et al. Antenatal Detection of Skeletal Dysplasias. J 
Ultras Med. 2003;22:255–258.  
 
[155] Geister KA, Camper SA. Advances in Skeletal Dysplasia Genetics. Annu Rev Genom 
Hum G. 2015;16:1–29.  
 
[156] Krakow D. Skeletal Dysplasias. Clin Perinatol. 2015;42:301–319.  
 
[157] Chitty LS, Mason S, Barrett AN, et al. Non‐invasive prenatal diagnosis of 
achondroplasia and thanatophoric dysplasia: next‐generation sequencing allows for a safer, 
more accurate, and comprehensive approach. Prenatal Diag. 2015;35:656–662.  
 
[158] Bellini C, Donarini G, Paladini D, et al. Etiology of non‐immune hydrops fetalis: An 
update. Am J Med Genet A. 2015;167:1082–1088.  
 
[159] Agakidis C, Agakidou E, Sarafidis K, et al. Immune Dysregulation, Polyendocrinopathy, 
Enteropathy, X-Linked Syndrome Associated With a Novel Mutation of FOXP3 Gene. 
Frontiers Pediatrics. 2019;7:20.  
 
[160] Shanes E, Propst L, Ouyang DW, et al. Recurrent Non-immune Fetal Hydrops 
Associated With IPEX Syndrome. Pediatric Dev Pathology Official J Soc Pediatric Pathology 




[161] Xavier-da-Silva M, Moreira-Filho CA, Suzuki E, et al. Fetal-onset IPEX: Report of two 
families and review of literature. Clin Immunol. 2015;156:131–140.  
 
[162] Schrander‐Stumpel C, Spruyt L, Curfs L, et al. Kabuki syndrome: Clinical data in 20 
patients, literature review, and further guidelines for preventive management. Am J Med 
Genet A. 2005;132A:234–243.  
 
[163] Long A, Sinkovskaya ES, Edmondson AC, et al. Kabuki syndrome as a cause of non‐
immune fetal hydrops/ascites. Am J Med Genet A. 2016;170:3333–3337.  
 
[164] Quinlan-Jones E, Lord J, Williams D, et al. Molecular autopsy by trio exome sequencing 
(ES) and postmortem examination in fetuses and neonates with prenatally identified 
structural anomalies. Genet Med. 2019;21:1065–1073.  
 
[165] Kamata S, Nose K, Ishikawa S, et al. Meconium peritonitis in utero. Pediatr Surg Int. 
2000;16:377–379.  
 
[166] Mandakini P, Ashwin D, Manisha R, et al. Urorectal septum malformation presenting 
as nonimmune hydrops fetalis. Prenatal Diag. 2006;26:582–584.  
 
[167] Kim C, Kim S, Yang Y, et al. A case of recurrent infantile polycystic kidney associated 




[168] Rodríguez MM, Chaves F, Romaguera RL, et al. Value of Autopsy in Nonimmune 
Hydrops Fetalis: Series of 51 Stillborn Fetuses. Pediatr Devel Pathol. 2002;5:365–374.  
 
[169] Çetinkaya M, Durmaz O, Büyükkale G, et al. Neonatal Bartter syndrome and unilateral 
ectopic renal cyst as new renal causes of hydrops fetalis: two case reports and review of the 
literature. J Maternal-fetal Neonatal Medicine. 2013;26:1147–1150.  
 
[170] Debray F-G, de Halleux V, Guidi O, et al. Neonatal Liver Cirrhosis Without Iron 
Overload Caused by Gestational Alloimmune Liver Disease. Pediatrics. 2012;129:e1076–
e1079.  
 
[171] da Rocha C, Guedes R, Kieling C, et al. Neonatal Liver Failure and Congenital Cirrhosis 
due to Gestational Alloimmune Liver Disease: A Case Report and Literature Review. Case 
Reports Pediatrics. 2017;2017:1–7.  
 
[172] Whitington PF, Kelly S, Taylor SA, et al. Antenatal Treatment with Intravenous 
Immunoglobulin to Prevent Gestational Alloimmune Liver Disease: Comparative 
Effectiveness of 14-Week versus 18-Week Initiation. Fetal Diagn Ther. 2018;43:218–225.  
 
[173] Kaiser I. Ballantyne and triple edema. Am J Obstet Gynecol. 1971;110:115–120.  
 
[174] Gedikbasi A, Oztarhan K, Gunenc Z, et al. Preeclampsia due to fetal non-immune 




[175] Navarro-Perez SF, Corona-Fernandez K, Rodriguez-Chavez JL, et al. Significant Clinical 
Manifestations in Ballantyne Syndrome, after a Case Report and Literature Review: 
Recognizing Preeclampsia as a Differential Diagnosis. Case Reports Obstetrics Gynecol. 
2019;2019:1–7.  
 
[176] Braun T, Brauer M, Fuchs I, et al. Mirror syndrome: a systematic review of fetal 
associated conditions, maternal presentation and perinatal outcome. Fetal Diagn Ther. 
2010;27:191–203.  
 
[177] Allarakia S, Khayat HA, Karami MM, et al. Characteristics and management of mirror 
syndrome: a systematic review (1956–2016). J Perinat Med. 2017;45:1013–1021.  
 
[178] Gherman R, Incerpi M, Wing D, et al. Ballantyne syndrome: is placental ischemia the 











Table 1. Structural cardiac malformations causing fetal hydrops. 
Structural heart disease  Pathophysiology of fetal hydrops 
Ebstein’s anomaly  Tricuspid valve regurgitation, impact on left 
ventricle 
Common arterial trunk with truncal 
valve stenosis  
Obstruction to left and right ventricles 
Hypoplastic left heart  If severe atrioventricular valve regurgitation, 
severely restrictive atrial septum  
Left atrial isomerism  Atrioventricular block or severe atrioventricular 
valve regurgitation  











Figure 1. 13 weeks gestation fetus showing significantly increased nuchal translucency 













Figure 2. 19 weeks gestation fetus demonstrating fetal hydrops with fluid seen accumulating in 
the abdominal cavity (ascites, blue arrow) as well as a small pericardial effusion (red arrow) and 









Figure 3. Illustration of the process by which a clinician may prioritise investigations to identify 
the underlying cause of fetal hydrops presenting after the first trimester. 
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